Phase II study of THR-317 in combination with an anti- VEGF agent for the treatment of diabetic macular edema.
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 10 Apr 2018 New trial record
- 06 Apr 2018 According to the ThromboGenics media release, company expects to initiate this trial in Q2 2018.